LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.16 USD | -2.61% |
|
+4.44% | -24.95% |
| May. 15 | Legend Expects to Log Profit in 2026 | MT |
| May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
Presenter SpeechJessie Yeung (Executives)Good morning, and welcome. This is Jessie Yeung, Head...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.16
USD
Average target price
85.2
USD
Spread / Average Target
+88.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.95% | 8.23B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- LEGN Stock
- News Legend Biotech Corporation
- Transcript : Legend Biotech Corporation - Special Call